Manufacturing cgmp grade hydroxycobalamine
Active Awarded Last action
- Contract number
- 75N91025F00021
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $730,402
Award facts
- Contract value 100% obligated
- $730,402.00 Current and potential, with all options
- Completion date 22% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $668,886 | |
| Original award | $61,516 |
About this award
The National Center for Advancing Translational Sciences issued a delivery order to Leidos Biomedical Research Inc. on September 15, 2025, with a ceiling value of $730,402 for manufacturing CGMP grade hydroxycobalamine. The order carries an ultimate completion date of September 14, 2030, and is priced on a cost-plus-fixed-fee basis with no set-aside.
Place of performance is Frederick, MD. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings Inc. and operates as a Federally Funded Research and Development Center (FFRDC) contractor delivering biomedical research and facilities support services to the National Institutes of Health. The company's specialized manufacturing capability spans monoclonal antibodies, gene therapy vector manufacturing, vaccine platform development, and chemistry, manufacturing, and controls development of therapeutic candidates.
Quick answers
Who was awarded contract 75N91025F00021?
75N91025F00021 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2025.
How much is contract 75N91025F00021 worth?
The government has obligated $730,402 on 75N91025F00021.
Which agency awarded contract 75N91025F00021?
National Cancer Institute (National Institutes of Health) awarded 75N91025F00021, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N91025F00021 an order under another contract?
Yes. 75N91025F00021 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00021 competed?
The extent of competition for 75N91025F00021 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award